Celltrion
068270.KS · Bio
Korea's pioneering biosimilar company. Developed Remsima, the world's first antibody biosimilar. Expanding into novel biologics and global direct sales through Celltrion Healthcare integration.
Latest news
Celltrion Plans 270 Billion Won Share Acquisition to Boost Shareholder Value
Today's Memo
Celltrion Completes 100 Billion Won Share Buyback Cancellation, Eyes 2 Trillion Won in Returns
Park Min-ji Tees Off in Pursuit of Record 21st KLPGA Win
Park Min-ji Reaches 20 KLPGA Wins, Eyes Solo Record
Celltrion Launches First Labor Union, Demands Bonus Transparency
Celltrion Files for Cosentyx Biosimilar Approval in Canada, Targets $10 Billion Market
Celltrion's U.S. Direct Sales Model Takes Hold, Fueling New Drug Push
Celltrion Nears End of Preclinical Trials for World-First Quadruple-Action Obesity Drug
Celltrion Files for Korean Approval of Subcutaneous Breast Cancer Drug Herzuma
Celltrion Unveils Next-Generation Drug Pipeline at Science & Innovation Day
Korean Pharma Firms Race to Adopt AI Across Drug Development
Celltrion Accelerates AI Adoption, Targeting Up to 90% Cut in Work Hours
K-Beauty Shines at Brazil's Largest Urban Cultural Festival
K-Bio Direct Sales Strategy Pays Off as US Subsidiaries' Earnings Soar
Korean Corporate Disclosures
Celltrion Launches Bonus Issue, Share Buyback to Boost Shareholder Value
Celltrion Vows Special Measures to Address Stock Undervaluation
Today's Memo
Celltrion Calls Stock "Excessively Undervalued," Vows to Review Shareholder Value Measures
Celltrion's Remsima Captures 70% of European Market
Celltrion Captures 70% of Europe's Infliximab Market with Remsima
